CD274 and breast neoplasm: In contrast, two neoadjuvant therapy combinations containing 6E11 (anti-PD-L1)—specifically, PTX+6E11 and PTX+B20+6E11—resulted in effective presurgical suppression of primary breast tumour growth (P < 0.05, Fig. 5a) as well as significant postsurgical OS benefits (Plog-rank < 0.05; Fig. 5b).